Prognostic values of four Notch receptor mRNA expression in gastric cancer

Xiaoyu Wu1*, Wentao Liu2*, Ding Tang3, Haijuan Xiao4, Zhenfeng Wu1, Che Chen1, Xuequan Yao2, Fukun Liu1 & Gang Li5

Notch ligands and receptors are frequently deregulated in several human malignancies including gastric cancer. The activation of Notch signaling has been reported to contribute to gastric carcinogenesis and progression. However, the prognostic roles of individual Notch receptors in gastric cancer patients remain elusive. In the current study, we accessed the prognostic roles of four Notch receptors, Notch 1–4, in gastric cancer patients through “The Kaplan-Meier plotter” (KM plotter) database, in which updated gene expression data and survival information include a total of 876 gastric cancer patients. All four Notch receptors’ high mRNA expression was found to be correlated to worsen overall survival (OS) for all gastric cancer patients followed for 20 years. We further accessed the prognostic roles of individual Notch receptors in different clinicopathological features using Lauren classification, pathological grades, clinical grades, HER2 status and different choices of treatments of gastric cancer patients. These results indicate that there are critical prognostic values of the four Notch receptors in gastric cancer. This information will be useful for better understanding of the heterogeneity and complexity in the molecular biology of gastric cancer and to develop tools to more accurately predict their prognosis.

Gastric cancer is the second most common cause of cancer-related death, and 800,000 cancer-related deaths are caused by gastric cancer each year globally1. Despite the advances in early detection, radical cure operation, and multimodal therapeutic modalities, at diagnosis, gastric cancer remains difficult to cure and prognosis remains poor with a median overall survival of 12 months for advanced disease in Western countries2-3. About 40–60% patients with gastric cancer received radical operation will often have postoperative recurrence and metastasis4. Therefore, in order to improve the clinical outcome of gastric cancer patients, the identification of the molecular mechanism during the incidence and progression of gastric cancer, as well as identification of prognostic biomarkers and drug targets are still needed and will help to select patients with higher chances of gastric cancer recurrence and provide better prognosis and individualized treatments.

The Notch signaling pathway is one of key pathways constituting the stem cell signaling network and is a highly conserved system that regulates cell-fate decisions and the maintenance of stem cells5-6. DLL1, DLL3, DLL4, JAG1 and JAG2, typical Notch ligands, and four Notch receptors (Notch 1–4) are frequently deregulated in several human malignancies and have been found in breast, colon, cervical, head and neck, lung, pancreatic, prostate cancer, ovarian cancer, renal carcinoma, acute myeloid, Hodgkin and Large-cell lymphomas, as well as gastric cancer7-11. A number of studies have shown that the activation of Notch signaling plays a critical role in gastric cancer initiation, progression and cross-talks with other signaling pathways, contributing to the apoptosis inhibition, development, angiogenesis, metastasis and chemoresistance of gastric cancer11-15. However, the prognostic roles of individual Notch receptors, especially at the mRNA level in gastric cancer patients remains elusive. In the current study, we accessed the prognostic roles of four Notch receptors in human gastric cancer patients by the Kaplan-Meier plotter (KM plotter).
KM plotter generated data from Gene Expression Omnibus (GEO-www.ncbi.nlm.nih.gov/geo/) database. This database includes gene expression data and survival information from a total of 876 gastric cancer patients. KM plotter can be utilized for the analysis of individual genes with clinical results to relapse-free survival and total survival of the patients. So far, a number of genes have been identified and/or validated by KM plotter in lung cancer19–22, breast cancer22–32, and ovarian cancer22,33,34. In this study, we used KM plotter database and accessed the prognostic roles of individual Notch receptor mRNA expression in human gastric cancer patients.

Material and Methods
An online database35 (http://kmplot.com/analysis/) was used to determine the relevance of individual Notch receptor mRNA expression to the overall survival (OS). OS is the length of time from either the date of diagnosis or the start of treatment for a cancer patient, that patients diagnosed with the cancer are still alive. In a clinical trial, measuring the OS is one of important ways to see how well a new treatment works. Currently, they established breast cancer35, lung cancer35, ovarian cancer36 and gastric cancer data. All cancer patients in the database were identified from Cancer Biomedical Informatics Grid (caBIG, http://cabig.cancer.gov/, microarray samples are published in the caArray project), the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov) cancer datasets35. They collected clinical data including gender, perforation history, Lauren classification, differentiation, stage, HER2 status and treatment. The database was established using gene expression data and survival information of 876 gastric cancer patients downloaded from Gene Expression Omnibus (GEO). Briefly, four Notch sub-members (Notch1, Notch2, Notch3 and Notch4) were entered into the database (http://kmplot.com/analysis/index.php?p=service&cancer=gastric) to obtain Kaplan-Meier survival plots in which the number-at-risk is indicated below the main plot. Hazard ratio (HR) and 95% confidence intervals, as well as log rank P were calculated and displayed on the webpage. P value of <0.05 was considered to be statistically significant. HR is the ratio of the hazard rates corresponding to the conditions described by two levels of an explanatory variable in survival analysis.

Results
Mammals possess four different notch receptors, referred to as Notch1, Notch2, Notch3 and Notch4. All Notch receptors Kaplan-Meier survival information can be found in www.kmplot.com. We first accessed the prognostic value of Notch1 mRNA expression in www.kmplot.com. The desired Affymetrix IDs is valid: 218902_at (Notch1). Survival curves were plotted for gastric cancer patients (n = 876) (Fig. 1A), for intestinal type cancer patients (n = 320) (Fig. 1B), and for diffuse type cancer patients (n = 241) (Fig. 1C). Notch1’s high mRNA expression was found to be correlated to worsen OS for all gastric cancer patients followed for 20 years, HR 1.38 (1.16–1.64),
p = 0.00022. Notch1 high mRNA expression was also found to be correlated to worsen OS in intestinal type cancer patients, HR 1.82 (1.25–2.64), p = 0.0014, but not in diffuse type cancer patients, HR 1.37 (0.96–1.94), p = 0.078.

We then accessed the prognostic value of Notch2 mRNA expression in www.kmplot.com. The desired Affymetrix IDs is valid: 210756_s_at (Notch2). Notch2’s high mRNA expression was found to be significantly correlated to worsen OS for all gastric cancer patients, HR 1.58 (1.31–1.89), p = 6.5e-07 (Fig. 2A), as well as in intestinal type cancer patients, HR 2.36 (1.72–3.25), p = 5.3e-08 (Fig. 2B), and in diffuse type cancer patients, HR 1.62 (1.15–2.28), p = 0.0051 (Fig. 2C).

Figure 3 showed the prognostic value of Notch3 mRNA expression in www.kmplot.com. The desired Affymetrix IDs is valid: 203237_at (Notch3). Notch3’s high mRNA expression was found to be significantly correlated to worsen OS for all gastric cancer patients, HR 1.6 (1.31–1.97), p = 0.0039 (Fig. 3B), and diffuse type cancer patients, HR 1.5 (1.06–2.11), p = 0.02 (Fig. 3C).

Figure 4 showed the prognostic value of Notch4 mRNA expression in www.kmplot.com. The desired Affymetrix IDs is valid: 205247_at (Notch4). Notch4’s high mRNA expression was also found to be significantly correlated to worsen OS for all gastric cancer patients, HR 1.98 (1.64–2.4), p = 9.3e-13 (Fig. 4A), intestinal type cancer patients, HR 2.47 (1.77–3.64), p = 4.6e-08 (Fig. 4B), and diffuse type cancer patients, HR 1.81 (1.18–2.11), p = 0.0054 (Fig. 4C).

For further access to the correlation of individual Notch receptors with other clinicopathological features, we accessed the correlation with gender (Table 1), pathological grades (Table 2), clinical grades (Table 3), HER2 status (Table 4) and different choices of treatments (Table 5) of gastric cancer patients. As from Table 1, all the individual Notch receptors did not show significant difference of prognosis in different gender positive gastric cancer patients. From Table 2, all the individual Notch receptors except Notch 2 were not significantly associated with pathological grades of gastric cancer patients. Notch 2’s high mRNA expression was associated with worsen OS in grade I gastric cancer patients, HR 10.5 (1.4–78.81), p = 0.0046. From Table 3, Notch 1’s high mRNA high expression was associated with worsen OS in grade II, HR 1.95 (1.04–3.64), p = 0.033 and grade III, HR 1.49 (1.07–2.06), p = 0.017. Notch 2’s high mRNA expression was associated with worsen OS in grade II, HR 2.26 (1.23–4.14), p = 0.0066 and grade III, HR 2.03 (1.46–2.82), p = 1.7e-05. Notch 3’s high mRNA expression was associated with worsen OS in grade I, HR 3.7 × 10^4 (0.0–inf), p = 0.0035, grade II, HR 2.32 (1.26–4.25), p = 0.0052 and grade III, HR 1.83 (1.31–2.54), p = 0.00028. From Table 4, all the individual Notch receptors except Notch 3 were significantly associated with worsen OS in either HER2 negative or HER2 positive gastric cancer patients. Notch 3’s high mRNA expression was only significantly associated with worsen OS in HER2 negative gastric cancer patients.
cancer patients, HR 1.57 (1.22–2.01), \( p = 0.00043 \). From Table 5, Notch 1’s high mRNA expression was associated with worsen OS in surgery alone gastric cancer patients, HR 1.4 (1.02–1.93), \( p = 0.037 \); as well as 5-FU based adjuvant gastric cancer patients, HR 1.53 (1.07–2.19), \( p = 0.019 \). Notch 2’s high mRNA expression was only associated with better OS in 5-FU based adjuvant gastric cancer patients, HR 0.61 (0.43–0.87), \( p = 0.0059 \). Notch 3’s high mRNA expression was only associated with worsen OS in surgery alone gastric cancer patients, HR 1.42 (1.00–2.02), \( p = 0.048 \). Notch 4’s high mRNA expression was also only associated with worsen OS in surgery alone gastric cancer patients, HR 2.12 (1.48–3.03), \( p = 2.7e-05 \).

**Discussion**

Among four Notch receptors and ligands, Notch 1 is relatively the most studied member of Notch signaling in gastric carcinogenesis\(^7,37–39\). With the active form of Notch 1, the Notch 1 intracellular domain (NICD) was frequently expressed in gastric cancer cell lines, and the depletion of Notch 1 by Notch 1 siRNA led to growth inhibition of gastric cancer cells\(^17,40\). Down-regulation of Notch 1 expression by gamma-secretase inhibition (N-[N-(3,5-difluoro phenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester, DAPT) was also able to substantially inhibit migration, invasion, and proliferation, as well as epithelial-mesenchymal transition in gastric cancer cell lines\(^41\). Changes in the expression of the Notch1 intracellular domain (NICD) differentially expressed in gastric cancer, and the aberrant expression of Notch1 NICD is associated with an advanced tumor stage, tumor metastasis and overall patient survival\(^42\). Du et al.\(^43\) performed a meta-analysis and showed that the expression of Notch1 protein was significantly higher in tumor tissues of gastric cancer compared to normal tissues. Specifically, stratified analyses showed that significantly increased expression of Notch1 was associated with non-cardia location, >5 cm size, diffuse type, positive lymphovascular invasion and distal metastasis, indicating that Notch1 protein may be an oncogene. Recently, Bauer et al.\(^44\) reported that primarily resected patients with Notch1 protein-negative tumors demonstrated worse prognosis in gastric cancer patients. However, whether or not Notch1 mRNA has a prognostic role in gastric cancer patients remains elusive. In this report, Notch1’s high mRNA expression was found to be correlated with worsen OS for all gastric cancer patients followed for 20 years. Notch1’s high mRNA expression was also found to be correlated to worsen OS in intestinal type cancer patients, but not in diffuse type cancer patients.

Notch2 activation was observed in 10.0% (1 of 10) of noncancerous endoscopic mucosa, 71.4% (30 of 42) in premalignant lesions, and 97.3% (72 of 74) in gastric cancer tissues, demonstrating a correlation of Notch2 expression with both intestinal and diffuse gastric cancer formation\(^45\). Constitutive expression of Notch2 NICD promoted both cell proliferation and xenografted tumor growth of human gastric adenocarcinoma SC-M1.
cells. Immunohistochemical analysis demonstrated a chemotherapy-associated increase in the intensity of Notch2 staining, indicating a prominent role for Notch2 in chemotherapy resistance of gastric cancer. Above results indicate that Notch2 seems to be a tumor oncogene in gastric carcinogenesis. Du et al. reported that the expression of Notch2 protein significantly was higher in tumor tissues of gastric cancer compared to normal tissues. However, Bauer et al. reported that higher Notch2 protein expression was associated with early-stage and intestinal-type tumors and with associated better survival in the subgroup of intestinal-type tumors. Their results support that Notch2 expression with early tumor stages suggest that Notch2 may act as a tumor suppressor in gastric cancer. However, there is no report about the prognostic significance of Notch2 mRNA expression in gastric cancer. In this report, Notch2’s high mRNA expression was found to be significantly correlated to worsen OS for all gastric cancer patients, as well as in intestinal type cancer patients and diffuse type cancer patients.

The study about Notch3 in gastric cancer is limited. The expression of Notch3 protein was observed to be associated with the intestinal/glandular differentiation of gastric carcinoma cells, suggesting a role as a possible favorable prognostic indicator. In this report, our results show that Notch3’s high mRNA expression was significantly correlated to worsen OS for all gastric cancer patients, as well as in intestinal type cancer patients and diffuse type cancer patients.

Figure 4. Determination of prognostic value of Notch4 mRNA expression in www.kmplot.com. The desired Affymetrix IDs is valid: 205247_at (Notch4). (A) Survival curves are plotted for all gastric cancer patients (n = 876). (B) Survival curves are plotted for intestinal type cancer patients (n = 320). (C) Survival curves are plotted for diffuse type cancer patients (n = 241).

| Notch receptors | Treatment | Cases | HR 95% CI     | P value |
|-----------------|-----------|-------|---------------|---------|
| Notch1          | Male      | 545   | 1.32 (1.06–1.63) | 0.012   |
|                 | Female    | 236   | 1.73 (1.22–2.47) | 0.0021  |
| Notch2          | Male      | 545   | 1.9 (1.51–2.38)  | 1.8e-08 |
|                 | Female    | 236   | 1.73 (1.12–2.67) | 0.012   |
| Notch3          | Male      | 545   | 1.49 (1.16–1.92) | 0.0019  |
|                 | Female    | 236   | 1.71 (1.13–2.59) | 0.011   |
| Notch4          | Male      | 545   | 2.21 (1.74–2.8)  | 3e-15   |
|                 | Female    | 236   | 2.43 (1.47–4.01) | 0.00032 |

Table 1. Correlation of Notch receptor mRNA high expression with gender of gastric cancer patients.
Same as Notch3, the study about Notch4 in gastric cancer is also limited. In a recent report, Notch4 activation was observed to promote gastric cancer growth in vitro and in vivo, while Notch4 inhibition using Notch4 siRNA had opposite effects. In addition, Notch4 activation induced expression and activation of Wnt1, β-catenin and downstream target genes, c-Myc and cyclin D1, in gastric cancer cells, while Notch4 inhibition had opposite effects. Wnt1 is one of WNT members that regulates various processes including tumor initiation, tumor growth,

| Notch receptors | Pathological grades | Cases | HR 95% CI | P value |
|-----------------|---------------------|-------|-----------|---------|
| Notch 1         | I                   | 32    | 2.18 (0.9–5.28) | 0.076   |
|                 | II                  | 67    | 0.76 (0.39–1.48) | 0.41    |
|                 | III                 | 165   | 1.31 (0.84–2.05) | 0.24    |
| Notch 2         | I                   | 32    | 10.5 (1.4–78.81) | 0.0046  |
|                 | II                  | 67    | 1.68 (0.87–3.21) | 0.12    |
|                 | III                 | 165   | 1.37 (0.92–2.05) | 0.12    |
| Notch 3         | I                   | 32    | 1.28 (0.54–3.03) | 0.57    |
|                 | II                  | 67    | 1.5 (0.76–2.97)  | 0.24    |
|                 | III                 | 165   | 1.3 (0.84–2.03)  | 0.24    |
| Notch 4         | I                   | 32    | 1.72 (0.69–4.27) | 0.24    |
|                 | II                  | 67    | 1.52 (0.79–2.94) | 0.24    |
|                 | III                 | 165   | 0.8 (0.53–1.2)   | 0.28    |

Table 2. Correlation of Notch receptor mRNA high expression with pathological grades of gastric cancer patients.

| Notch receptors | Clinical stages | Cases | HR 95% CI | P value |
|-----------------|-----------------|-------|-----------|---------|
| Notch 1         | 1               | 67    | 3.17 (0.9–11.19) | 0.058   |
|                 | 2               | 140   | 1.95 (1.04–3.64) | 0.033   |
|                 | 3               | 305   | 1.49 (1.07–2.06) | 0.017   |
|                 | 4               | 148   | 0.73 (0.49–1.07) | 0.1     |
| Notch 2         | 1               | 67    | 2.1 (0.75–5.83)  | 0.15    |
|                 | 2               | 140   | 2.26 (1.23–4.14) | 0.0066  |
|                 | 3               | 305   | 2.03 (1.46–2.82) | 1.7e-05 |
|                 | 4               | 148   | 1.33 (0.87–2.03) | 0.19    |
| Notch 3         | 1               | 67    | 2.76 (0.79–9.71) | 0.098   |
|                 | 2               | 140   | 0.55 (0.28–1.08) | 0.077   |
|                 | 3               | 305   | 1.8 (1.26–2.57)  | 0.0011  |
|                 | 4               | 148   | 1.4 (0.94–2.11)  | 0.1     |
| Notch 4         | 1               | 67    | 3.7 × 10^9 (0.0–inf) | 0.0035  |
|                 | 2               | 140   | 2.32 (1.26–4.25) | 0.0852  |
|                 | 3               | 305   | 1.83 (1.31–2.54) | 0.0028  |
|                 | 4               | 148   | 1.56 (0.97–2.51) | 0.062   |

Table 3. Correlation of Notch receptor mRNA high expression with clinical stages of gastric cancer patients.

| Notch receptors | HER2 status | Cases | HR 95% CI | P value |
|-----------------|-------------|-------|-----------|---------|
| Notch 1         | Negative    | 532   | 1.32 (1.05–1.65) | 0.016   |
|                 | Positive    | 344   | 1.58 (1.2–2.09)  | 0.0011  |
| Notch 2         | Negative    | 532   | 1.53 (1.22–1.93) | 0.00023 |
|                 | Positive    | 344   | 1.44 (1.07–1.96) | 0.017   |
| Notch 3         | Negative    | 532   | 1.57 (1.22–2.01) | 0.00043 |
|                 | Positive    | 344   | 1.31 (0.98–1.76) | 0.065   |
| Notch 4         | Negative    | 532   | 2.03 (1.61–2.57) | 1.7e-09 |
|                 | Positive    | 344   | 1.62 (1.25–2.1)  | 0.00025 |

Table 4. Correlation of Notch receptor mRNA high expression with HER2 status of gastric cancer patients.
Notch 4 worsen OS in surgery alone gastric cancer patients and 5-FU based adjuvant gastric cancer patients. In this study, we observed that Notch expression status could also impact the treatment efficiency of 5-FU based adjuvant therapy and/or prognosis of gastric cancer patients. In this report, we observed that Notch4’s high mRNA expression was also found to be significantly correlated to worsen OS for all gastric cancer patients, intestinal type cancer patients, and diffuse type of cancer patients. In summary, by using the KM plotter database, we accessed the prognostic roles of four Notch receptors in gastric cancer patients through KM plotter, in which updated gene expression data and survival information included data from a total of 876 gastric cancer patients. All four Notch receptors’ high mRNA expression was found to be correlated to worsen overall survival (OS) for all gastric cancer patients followed for 20 years. We further accessed the prognostic roles of individual Notch receptors in different clinicopathological features including Lauren classification, pathological grades, clinical grades, HER2 status and different choices of treatments of gastric cancer patients. These results indicate that there are critical prognostic values of Notch 1–4 receptors in worsen OS in HER2 negative gastric cancer patients. Interestingly, Notch 2’s high mRNA expression is only associated with worsen OS in surgery alone gastric cancer patients and 5-FU based adjuvant gastric cancer patients. Notch 3 and Notch 4’s high mRNA expression is only associated with worsen OS in surgery alone for gastric cancer patients. This information will be useful for the better understanding of the heterogeneity and complexity in the molecular biology of gastric cancer and to develop tools to more accurately predict their prognosis.

**Table 5.** Correlation of Notch receptor mRNA high expression with different treatment of gastric cancer patients.

| Notch receptors | Treatment | Cases | HR 95% CI | P value |
|-----------------|-----------|-------|-----------|---------|
| Notch1          | Surgery alone | 380   | 1.4 (1.02–1.93) | 0.037   |
|                 | 5-FU based Adjuvant | 153   | 1.53 (1.07–2.19) | 0.019   |
| Notch2          | Surgery alone | 380   | 1.34 (0.98–1.85) | 0.068   |
|                 | 5-FU based Adjuvant | 153   | 0.61 (0.43–0.87) | 0.0059  |
| Notch3          | Surgery alone | 380   | 1.42 (1.00–2.02) | 0.048   |
|                 | 5-FU based Adjuvant | 153   | 0.82 (0.56–1.21) | 0.31    |
|                 | Surgery alone | 380   | 2.12 (1.48–3.03) | 2.7e–05 |
| Notch4          | 5-FU based Adjuvant | 153   | 1.22 (0.85–1.74) | 0.27    |

References

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69–90 (2011).
2. Yang, W., Raufi, A. & Klempner, S. J. Targeted therapy for gastric cancer: Molecular pathways and ongoing investigations. Biochim Biophys Acta 22, 00048–00041 (2014).
3. Obi, K. et al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer 49, 1565–1577 (2013).
4. Cao, Y., DePinho, R. A., Ernst, M. & Vousden, K. Cancer research: past, present and future. Nat Rev Cancer 11, 749–754, doi: 10.1038/nrc3138 (2011).
5. Lewis, I. Notch signalling and the control of cell fate choices in vertebrates. Semin Cell Dev Biol 9, 583–589, doi: S1084-9521(98)90266-X (1998).
6. Simpson, P. Developmental genetics. The Notch connection. Nature 375, 736–737, doi: 10.1038/375736a0 [doi] (1995).
7. Katoh, M. Notch signaling in gastrointestinal tract (review). Int J Oncol 30, 247–251 (2007).
8. Kopan, R. & Ilagan, M. X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216–233, doi: S0092-8674(09)00382-1 (2009).
9. Miele, L. Notch signaling. Clin Cancer Res 12, 1074–1079, doi: 12/4/1074 (2006).
10. Miele, L., Miao, H. & Nickoloff, B. J. NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 6, 313–323 (2006).
11. Alkiri, A. & Attoub, S. Notch Signaling in Cancer: Rationale and Strategies for Targeting. Curr Cancer Drug Targets 15, 364–374, doi: C10.1080/1568006X.2015.1060537.015792 (2015).
49. Qian, C.
53. Chiurillo, M. A. Role of the Wnt/beta-catenin pathway in gastric cancer: An in-depth literature review.
48. Kang, H.
51. You, L.
47. Bauer, L.
45. Sun, Y.

37. Chen, D. H., Yu, J. W. & Jiang, B. J. Contactin 1: A potential therapeutic target and biomarker in gastric cancer.
36. Gyorffy, B., Lanczky, A. & Szallasi, Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in

28. Maciejczyk, A.
27. Maciejczyk, A.
25. Zhou, C.
24. Tilghman, S. L.
23. Liu, M., Wang, G., Gomez-Fernandez, C. R. & Guo, S. GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in

12. Chiaramonte, R.
18. Yan, B.
16. Zhou, M.
15. Yu, J.
14. Chu, J.
13. Gao, R.
12. Chiaramonte, R.
11. Li, Y.
10. Ren, J.
9. Chen, Z. H.

8. Ng, Y. C. K., Ng, H. K. & Chen, Y. G. Distinct prognostic values and potential diagnostic targets of ALDH1 isoenzymes in non-small cell lung cancer.

51, doi: 10.2147/DDDT.S87197 (2015).
50. Dotsch, M. M.
49. Qian, C.
43. Chae, J. Y.
42. Song, D. H.
41. Song, K. W.
40. Chen, Z. H.
39. Zhang, Q.
38. Chen, Y. C.
37. Chen, D. H., Yu, J. W. & Jiang, B. J. Contactin 1: A potential therapeutic target and biomarker in gastric cancer.
36. Gyorffy, B., Lanczky, A. & Szallasi, Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in

29. Mack, S.
28. Maciejczyk, A.
27. Maciejczyk, A.
26. Maciejczyk, A.
25. Zhou, C.
24. Tilghman, S. L.
23. Liu, M., Wang, G., Gomez-Fernandez, C. R. & Guo, S. GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in

19. Zhang, Q.
18. Yan, B.
17. Tang, X.
16. Zhou, M.
15. Yu, J.
14. Chu, J.
13. Gao, R.
12. Chiaramonte, R.
11. Li, Y.
10. Ren, J.
9. Chen, Z. H.

8. Ng, Y. C. K., Ng, H. K. & Chen, Y. G. Distinct prognostic values and potential diagnostic targets of ALDH1 isoenzymes in non-small cell lung cancer.

51, doi: 10.2147/DDDT.S87197 (2015).
50. Dotsch, M. M.
49. Qian, C.
43. Chae, J. Y.
42. Song, D. H.
41. Song, K. W.
40. Chen, Z. H.
39. Zhang, Q.
38. Chen, Y. C.
37. Chen, D. H., Yu, J. W. & Jiang, B. J. Contactin 1: A potential therapeutic target and biomarker in gastric cancer.
36. Gyorffy, B., Lanczky, A. & Szallasi, Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in

29. Mack, S.
28. Maciejczyk, A.
27. Maciejczyk, A.
26. Maciejczyk, A.
25. Zhou, C.
24. Tilghman, S. L.
23. Liu, M., Wang, G., Gomez-Fernandez, C. R. & Guo, S. GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in

19. Zhang, Q.
18. Yan, B.
17. Tang, X.
16. Zhou, M.
15. Yu, J.
14. Chu, J.
13. Gao, R.
12. Chiaramonte, R.
11. Li, Y.
10. Ren, J.
9. Chen, Z. H.

8. Ng, Y. C. K., Ng, H. K. & Chen, Y. G. Distinct prognostic values and potential diagnostic targets of ALDH1 isoenzymes in non-small cell lung cancer.

51, doi: 10.2147/DDDT.S87197 (2015).
50. Dotsch, M. M.
49. Qian, C.
43. Chae, J. Y.
42. Song, D. H.
41. Song, K. W.
40. Chen, Z. H.
39. Zhang, Q.
38. Chen, Y. C.
37. Chen, D. H., Yu, J. W. & Jiang, B. J. Contactin 1: A potential therapeutic target and biomarker in gastric cancer.
36. Gyorffy, B., Lanczky, A. & Szallasi, Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in

29. Mack, S.
28. Maciejczyk, A.
27. Maciejczyk, A.
26. Maciejczyk, A.
25. Zhou, C.
24. Tilghman, S. L.
23. Liu, M., Wang, G., Gomez-Fernandez, C. R. & Guo, S. GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in

19. Zhang, Q.
18. Yan, B.
17. Tang, X.
16. Zhou, M.
15. Yu, J.
14. Chu, J.
13. Gao, R.
12. Chiaramonte, R.
11. Li, Y.
10. Ren, J.
9. Chen, Z. H.

8. Ng, Y. C. K., Ng, H. K. & Chen, Y. G. Distinct prognostic values and potential diagnostic targets of ALDH1 isoenzymes in non-small cell lung cancer.

51, doi: 10.2147/DDDT.S87197 (2015).
50. Dotsch, M. M.
49. Qian, C.
43. Chae, J. Y.
42. Song, D. H.
41. Song, K. W.
40. Chen, Z. H.
39. Zhang, Q.
38. Chen, Y. C.
37. Chen, D. H., Yu, J. W. & Jiang, B. J. Contactin 1: A potential therapeutic target and biomarker in gastric cancer.
36. Gyorffy, B., Lanczky, A. & Szallasi, Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in

29. Mack, S.
28. Maciejczyk, A.
27. Maciejczyk, A.
26. Maciejczyk, A.
25. Zhou, C.
24. Tilghman, S. L.
23. Liu, M., Wang, G., Gomez-Fernandez, C. R. & Guo, S. GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in

19. Zhang, Q.
18. Yan, B.
17. Tang, X.
16. Zhou, M.
15. Yu, J.
14. Chu, J.
13. Gao, R.
12. Chiaramonte, R.
11. Li, Y.
10. Ren, J.
9. Chen, Z. H.
54. Casimiro, M. C., Velasco-Velazquez, M., Aguirre-Alvarado, C. & Pestell, R. G. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Expert Opin Investig Drugs 23, 295–304, doi: 10.1517/13543784.2014.867017 (2014).
55. Feakins, R. M., Nickols, C. D., Bidd, H. & Walton, S. J. Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol 34, 1276–1282, doi: S0046817703004726 (2003).
56. Pradeep, A. et al. Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells. Oncogene 23, 3689–3699, doi: 10.1080/sj.onc.1207454 (2004).
57. Tai, W., Mahato, R. & Cheng, K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release, doi: S0168-3659(10)00263-4 (2010).
58. Tzahar, E. & Yarden, Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1377, M25–37, doi: S0304-419X(97)00032-2 (1998).
59. Ruschoff, J. et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 25, 637–650, doi: modpathol2011198 (2012).
60. Rajagopal, I., Niveditha, S. R., Sahadev, R., Nagappa, P. K. & Rajendra, S. G. HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas. J Clin Diagn Res 9, EC06–10, doi: 10.7860/JCDR/2015/12581.5630 (2015).
61. Yao, J. et al. Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT/beta-catenin. Cancer Biol Ther 14, 833–839, doi: 25332 (2013).
62. Hong, K. J., Wu, D. C., Cheng, K. H., Chen, L. T. & Hung, W. C. RECK inhibits stemness gene expression and tumorigenicity of gastric cancer cells by suppressing ADAM-mediated Notch1 activation. J Cell Physiol 229, 191–201, doi: 10.1002/jcp.24434 (2014).

Acknowledgements
This research was supported in part by National Science Foundation of China (81402523 to XW, 81201797 to GL), Jiangsu Province “Six adults just” high peak (2009-D-63 to GL), Youth Projects of Jiangsu Provincial Health Department (H201065 to GL), and the Natural Science Foundation of Jiangsu Province (BK2009445 to GL).

Author Contributions
X.W., W.L. and G.L. participated in the design of the study and drafted the manuscript. X.W., W.L., Z.W., C.C., X.Y. and F.L. reviewed and extracted data. X.W., W.L., D.T., H.X. and Z.W. participated in the research of the study and performed the statistical analysis. All authors reviewed the manuscript.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Wu, X. et al. Prognostic values of four Notch receptor mRNA expression in gastric cancer. Sci. Rep. 6, 28044; doi: 10.1038/srep28044 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/